Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 5/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NCF1 | P14598 | 3/20 | 0.42 |
| ▸ | CD38 | P28907 | 1/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058746 | 0.87 | AGTR1 (0.50) | ACP1CYP2C19MEN1KMT2ANCF1 | |
| SCHEMBL9709621 | 0.79 | AGTR1 (0.44) | MEN1KMT2ACD38AGTR1AGTR2 | |
| SCHEMBL3054345 | 0.77 | CD38 (0.53) | ACP1CYP2C19MEN1KMT2ACD38 | |
| SCHEMBL9709904 | 0.77 | AGTR1 (0.46) | ACP1CYP2C19MEN1KMT2AAGTR1 | |
| SCHEMBL9709642 | 0.77 | AGTR1 (0.48) | MEN1KMT2ACD38AGTR1AGTR2 | |
| SCHEMBL3058825 | 0.76 | CYP2C19 (0.64) | ACP1CYP2C19MEN1KMT2ANCF1 | |
| SCHEMBL9709854 | 0.76 | MEN1 (0.63) | ACP1MEN1KMT2ANCF1AGTR1 | |
| SCHEMBL9709759 | 0.76 | AGTR1 (0.45) | ACP1MEN1KMT2AAGTR1AGTR2 | |
| SCHEMBL9709757 | 0.75 | AGTR1 (0.52) | ACP1NCF1AGTR1AGTR2 | |
| SCHEMBL9709600 | 0.75 | AGTR1 (0.48) | MEN1KMT2ACD38AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420670-B2 | 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2013-04-16 | — | — | US | claimed |
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-09-02 | — | — | US | claimed |
| EP-2178842-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | Abbott GmbH & Co. KG (DE) | 2010-04-28 | — | — | EP | claimed |
| WO-2009024611-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2009-02-26 | — | — | WO | claimed |
| US-8420670-B2 | 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2013-04-16 | — | — | US | disclosed |
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-09-02 | — | — | US | disclosed |
| EP-2178842-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | Abbott GmbH & Co. KG (DE) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009024611-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | GDI2, GDI1, NQO2 | ACP1 4703/4885CYP2C19 39/4885MEN1 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.